Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Ranibizumab versus Bevacizuma...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Bibliographic Details
Main Authors:
Chakravarthy, U
,
Harding, S
,
Rogers, C
,
Downes, S
,
Lotery, A
,
Wordsworth, S
,
Reeves, B
Format:
Journal article
Published:
2012
Holdings
Description
Similar Items
Staff View
Similar Items
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
by: Chakravarthy, U, et al.
Published: (2012)
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
by: Chakravarthy, U, et al.
Published: (2012)
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
by: Dakin, H, et al.
Published: (2014)
Quality of fixation in eyes with neovascular age-related macular degeneration treated with ranibizumab.
by: Sivaprasad, S, et al.
Published: (2011)
Treat-And-extend bevacizumab for neovascular age-related macular degeneration: The importance of baseline characteristics
by: Rush, R, et al.
Published: (2014)